EyePoint Pharmaceuticals (EYPT) said late Tuesday it priced a public offering of about 12.7 million shares at $11 apiece for gross proceeds of about $140 million, up from the initial proposed size of $100 million.
Underwriters have been granted a 30-day option to purchase up to about 1.9 million additional shares.
The offering, expected to close around Thursday, will fund the clinical development of Duravyu for wet age-related macular degeneration and diabetic macular edema, support early-stage pipeline initiatives and cover general corporate expenses.
Price: 11.53, Change: -0.01, Percent Change: -0.09
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.